Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12610000744055
Ethics application status
Approved
Date submitted
1/09/2010
Date registered
7/09/2010
Date last updated
28/06/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Garlic and Candida: A Randomised Controlled Trial (PAThWAY Study)
Scientific title
A randomised controlled study comparing the effect of oral garlic tablets compared to oral placebo tablets on vaginal colonisation with Candida in women of childbearing age with a history of vulvovaginal candidiasis
Secondary ID [1] 252460 0
Nil
Universal Trial Number (UTN)
U1111-1116-6012
Trial acronym
PAThWAY
(Potential Alternative Therapy: Women, Allicin, Yeast)
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Recurrent vulvovaginal candidiasis 257976 0
Condition category
Condition code
Alternative and Complementary Medicine 258135 258135 0 0
Herbal remedies
Skin 258136 258136 0 0
Dermatological conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
3 garlic tablets (enteric coated tablets containing 350mg garlic powder) twice a day, with total daily dose of 2,100mg (6 tablets) per day for 2 weeks. The pilot study for this trial has already been registered (ACTRN12610000532000).
Intervention code [1] 257023 0
Treatment: Drugs
Intervention code [2] 257028 0
Prevention
Intervention code [3] 257157 0
Treatment: Other
Comparator / control treatment
3 lactose placebo tablets twice a day, with a total of 6 tablets per day
Control group
Placebo

Outcomes
Primary outcome [1] 258999 0
Vaginal colonisation with Candida in intervention and control groups assessed by daily vaginal swabs for 14 days during the luteal part of the menstrual cycle, for one cycle only, until menstruation.
Timepoint [1] 258999 0
Daily colony counts of Candida from day 14-28 of the menstrual cycle for one cycle only
Secondary outcome [1] 265225 0
Comparison of daily diary with daily quantitative colony counts of Candida to ascertain whether medications (e.g.antibiotics, vaginal creams etc) diet, sexual activity or other physical activity correlates with colony counts of Candida
Timepoint [1] 265225 0
Daily diary will be kept by each participant throughout the 2 weeks of the study, for approximately 14 days in the second half of the menstrual cycle until menstruation.

Eligibility
Key inclusion criteria
18-50 years, of reproductive age
Previous history of vulvovaginal candidiasis (VVC)
Asymptomatic for vaginitis (i.e. no abnormal vaginal discharge or itchiness)
Able to take two vaginal swabs and post them daily for approximately 14 days
Able and willing to take 2 herbal tablets twice a day for approximately 14 days
Agree not to self medicate with over the counter medications, herbal or complementary medicines, and abstain from added garlic in diet for the duration of the study
Minimum age
18 Years
Maximum age
50 Years
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Allergy to garlic
Bleeding disorders / taking warfarin / peptic ulcers
Intended surgery during or immediately after the study period
Pregnant or breastfeeding

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Randomisation schedule will be devised by statistician at Dept of General Practice, University of Melbourne. This schedule will be given directly to pharmacist at Royal Women's Hospital, who allocates placebo/intervention according to schedule. The containers are then sealed and given to researcher for distribution in order of enrolment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation will be performed by using a randomisation table created by a computer software (i.e., computerised sequence generation).

Participants respond to advertisement. Eligibility will be determined via direct communication with participant. Eligible women sent plain language statement, consent form and entry questionnaire.
Simple randomisation will be performed by using a randomisation table created by a computer software (i.e., computerised sequence generation).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
none
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
10/09/2010
Actual
1/10/2010
Date of last participant enrolment
Anticipated
Actual
14/07/2011
Date of last data collection
Anticipated
Actual
14/07/2011
Sample size
Target
60
Accrual to date
Final
47
Recruitment in Australia
Recruitment state(s)
Recruitment postcode(s) [1] 3141 0
3053

Funding & Sponsors
Funding source category [1] 257477 0
Charities/Societies/Foundations
Name [1] 257477 0
Shepherd Foundation
Country [1] 257477 0
Australia
Primary sponsor type
University
Name
University of Melbourne
Address
Department of General Practice
University of Melbourne
200 Berkeley St, Carlton 3053 VIC
Country
Australia
Secondary sponsor category [1] 256705 0
University
Name [1] 256705 0
Royal Melbourne Institute of Technology (RMIT)
Address [1] 256705 0
RMIT University Building 223
Level 1, Bundoora Campus Plenty Road
Bundoora, 3083 VIC
Country [1] 256705 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 259504 0
Royal Women's Hospital
Ethics committee address [1] 259504 0
Ethics committee country [1] 259504 0
Australia
Date submitted for ethics approval [1] 259504 0
Approval date [1] 259504 0
03/05/2010
Ethics approval number [1] 259504 0
09/55
Ethics committee name [2] 259505 0
University of Melbourne
Ethics committee address [2] 259505 0
Ethics committee country [2] 259505 0
Australia
Date submitted for ethics approval [2] 259505 0
Approval date [2] 259505 0
28/08/2010
Ethics approval number [2] 259505 0
0932243.1

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 31529 0
Address 31529 0
Country 31529 0
Phone 31529 0
Fax 31529 0
Email 31529 0
Contact person for public queries
Name 14776 0
Cathy Watson
Address 14776 0
Department of General Practice
University of Melbourne
200 Berkeley St, Carlton 3052
Victoria
Country 14776 0
Australia
Phone 14776 0
+61 3 9035 5685
Fax 14776 0
+61 3 9347 6136
Email 14776 0
[email protected]
Contact person for scientific queries
Name 5704 0
Cathy Watson
Address 5704 0
Department of General Practice
University of Melbourne
200 Berkeley St, Carlton 3052
Victoria
Country 5704 0
Australia
Phone 5704 0
+61 3 9035 5685
Fax 5704 0
+61 3 9347 6136
Email 5704 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.